Blood biomarkers in cardioembolic stroke

Current Cardiology Reviews

Volumn 6, Issue 3, 2010, Pages 194-201

  García Berrocoso, Teresa ^a   Fernández Cadenas, Israel ^a   Delgado, Pilar ^a   Rosell, Anna ^a   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarker; Cardioembolic; Classification; Etiology; Natriuretic peptides; Stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; ANGIOPOIETIN 2; APELIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CD63 ANTIGEN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOPEPTIDE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; N(G),N(G) DIMETHYLARGININE; NEUROPEPTIDE Y; THROMBOCYTE FACTOR 4; TRANSCRIPTION FACTOR PITX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ARTERY EMBOLISM; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ECHOGRAPHY; ELECTROCARDIOGRAM; HEART FUNCTION; HEART RHYTHM; HOLTER MONITORING; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; STROKE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 77956551214     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310791658767     Document Type: Article

References (53)

1. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Searching for oracles? Blood biomarkers in acute stroke. Neurology 2009; 73(5):393-9
2. Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke 2006; 37: 769-75
3. Zivin JA: Acute stroke therapy with tissue plasmino gen activator(tPA) since it was approved by the U.S. Food and Drug Administration (FDA). Ann Neurol 2009; 66(1): 6-10
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-29
5. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis 2009; 27:493-501
6. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in amulti center clinical trial. Stroke 1993; 24: 35-41
7. Gordon DL, Bendixen BH, Adams HP, Clarke W, Kappelle LJ, Woolson RF. Inter physician agreement in the diagnosis of sub typesof acute ischemic stroke: implications for clinical trials. Neurology 1993; 43: 1021-7
8. Bogousslavsky J, Van Melle G, Regli F. The Laussane Stroke Registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988; 19: 1083-92
9. Touboul PJ, Elbaz A, Koller C, Lucas C, Adraï V, Chédru F, Amarenco P. Common carotid artery intima-media thickness and is chemic stroke sub types: the GÉNIC case-control study.Circulation 2000; 102: 313-8
10. Ay H, Furie KL, Singhal A, Smith WS, Sorensen G, Koroshetz WJ. An evidence-based causative classification system for acute is chemic stroke. Ann Neurol 2005; 58: 688-97
11. Ay H, Benner T, Arsava EM, Furie KL, et al. A computerize dalgorithm for etiologic classification of ischemic stroke. The Causative Classification of Stroke System. Stroke 2007; 38: 2979-84
12. http://ccs.martinos.org
13. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005;111: 570-5
14. Xu H, Tang Y, Liu DZ, et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of is chemic stroke. J Cereb Blood Flow Metab 2008; 28: 1320-8
15. Becker RC: Biomarkers in atrial fibrillation: Investigating biologic plausibility, cause, and effect. J Thromb Thrombol 2005; 19(1): 71-5
16. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008;39: 2280-7
17. Ageno W, Finazzi S, Steidl L, et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke sub types.Arch Intern Med 2002; 162(22): 2589-93
18. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardio embolic stroke from other stroke types in acute ischemic stroke. Intern Med 2009; 48(5): 259-64
19. Rodríguez-Yáñez M, Sobrino T, Blanco M, et al High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardio embolic origin in undetermined stroke. Dis Markers 2009; 26: 189-95
20. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009; 101: 929-37
21. Young B, Gleeson M, Cripps AW. C-reactive protein: A criticalreview. Pathology 1991; 23: 118-24
22. Yeh ETH, Khan BV. The potential role of antiplatelet agents inmodulating inflammatory markers in atherothrom bosis. J Thromb Haemost 2006; 4: 2308-16
23. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005; 19(1): 130-8
24. Terruzzi A, Valente L, Mariani R, Moschini L, Camerlingo M. C-reactive protein and a etiological subtypes of cerebral infarction. Neurol Sci 2008; 29: 245-9
25. Isaac TT, Dokainish H, Lakkis NM. Role of inflammation ininitiation and perpetuation of atrial fibrillation. A systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-8
26. Petersen NH, Schmied AB, Zeller JA, Plendl H, Deuschl G, Zunker P. Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. Cerebrovasc Dis 2007; 23:188-93
27. Tsai NW, Chang WN, Shaw CF, et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009; 124(2): 213-8
28. Dai DF, Thajeb P, Tu CF, et al. Plasma concentration of SCUBE1, an ovel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. J Am Coll Cardiol 2008; 51(22):2173-80
29. Choudhury A, Freestone B, Patel J, Lip GYH. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation. A link among platelet activation, angiogenesis, and thrombosis? Chest 2007; 132:1913-9
30. Choudhury A, Chung I, Blann AD, Lip GYH. Platelet surfaceCD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation. Acomparison of "healthy control subjects" and "disease controlsubjects" in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957-64
31. Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Fetuin-Aand CD40L plasma levels in acute ischemic stroke: differences inrelation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010; 208(1): 290-6
32. Brea D, Sobrino T, Blanco M, et al. Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrom boticischemic stroke diagnosis confirmation. Atherosclerosis 2009; 205:561-7
33. Blanco M, Moro MA, Dávalos A, et al. Increased plasma levels of15-deoxyDelta prostaglandin J2 are associated with good outcomein acute atherothrombotic ischemic stroke. Stroke 2005; 36(6):1189-94
34. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile ofmicroRNAs in young stroke patients. PLoS One 2009; 4(11):e7689
35. Nikolaos K, Ioanna M, Vasilios K, Jan H, Konstantinos K. Common CCR 5 polymorphism in stroke: the CCR 5 delta32polymorphism differentiates cardioembolism from other aetiologiesof ischaemic cerebrovascular diseases. Scand J Immunol 2009;70(5): 475-80
36. Gudbjartsson DF, Arnar DO, Helgadottir A, I et al. Variants conferring risk of a trial fibrillation on chromosome 4q25. Nature 2007; 448 (7151): 353-7
37. Gretarsdottir S, Thorleifsson G, Manolescu A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol 2008; 64(4): 402-9
38. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with a trial fibrillation and ischemic stroke. Nat Genet 2009; 41(8): 876-8
39. Kaplan RC, McGinn AP, Baird AE, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmen opausal women: the Women's Health Initiative observational study. J Stroke Cerebrovasc Dis 2008; 17(6): 344-55
40. Marcovina SM, Crea F, Davignon J, et al. Biochemical and bio imaging markers for risk assessment and diagnosis in majorcardiovascular diseases: a road to integration of complementary diagnostic tools. J Intern Med 2007; 261: 214-34
41. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008; 72: 1120-4
42. Ellinor PT, Low AF, MacRae CA. Reduced ap elin levels in loneatrial fibrillation. Eur Heart J 2006; 27: 222-6
43. Xia W, Qu X, Yu Y, Zhang X, Feng W, Song Y. A symmetric dimethylarginine concentration and early recurrence of a trial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol 2008; 31: 1036-40
44. Naya T, Yukiiri K, Hosomi N, et al. Brain natriuretic peptide as a surrogate marker for cardio embolic stroke with paroxysmal a trial fibrillation. Cerebrovasc Dis 2008; 26: 434-40
45. Yukiiri K, Hosomi N, Naya T, et al. Plasma brain natriuretic peptide as a surrogate marker for cardio embolic stroke. BMCNeurol 2008; 8: 45
46. Tziakas DN, Chalikias GK, Papanas N, Stakos DA, Chatzikyriakou SV, Maltezos E. Circulating levels of collagen type I degradation marker depend on the type of a trial fibrillation. Euro pace 2007; 9:589-96
47. Roldán V, Marín F, González-Conejero R, et al. Factor VII-323decanucleotide D/I polymorphism in a trial fibrillation: Implications for the prothrombotic state and stroke risk. Ann Med 2008; 40(7):553-9
48. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GYH. SolubleE-selectin, von Wille brand factor, soluble thromb omodulin, and total body nitrate/nitrite product as indices of end othelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253-8
49. Marín F, Roldán V, Climent V, García A, Marco P, Lip GYH. Isthrombogenesis in atrial fibrillation related to matrix metallo-proteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34: 1181-6
50. Gartner W, Zierhut B, Mineva I, et al. Brain natriuretic peptidecorrelates with the extent of atrial fibrillation-associated silent brain lesions. Clin Biochem 2008; 41: 1434-9
51. Choudhury A, Chung I, Blann AD, Lip GYH. Elevated plateletmicroparticle levels in nonvalvular atrial fibrillation. Chest 2007;131: 809-15
52. On YK, Jeon ES, Lee SY, et al. Plasma transforming growth factorb1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg 2009; 137: 1515-20
53. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrialfibrillation on plasma von Willebrand factor, soluble E-selectin, andN-terminal pro B-type natriuretic peptide levels in systolic heartfailure. Chest 2008; 133: 1203-8.